Sciessent to Discuss the Effectiveness of Antimicrobial-Embedded Medical Devices at Upcoming Industry Conferences
Wakefield, Mass. (PRWEB) September 10, 2015 -- According to the CDC, more than two million people become ill with antibiotic-resistant infections each year. These startling statistics have forced organizations across the healthcare industry to find new strategies and technologies to vastly improve infection control. With medical devices being one of the most common conduits, manufacturers are increasingly looking to embed antimicrobials into the surfaces of medical devices to combat against antibiotic-resistant infections. Lise Moloney, the director of business development, healthcare, at Sciessent, the leading provider of antimicrobial solutions, will be discussing this topic in more detail at two upcoming industry conference.
At Medical Grade Polymers, Sept. 15-16, in Boston, Moloney will present, “Evaluating the Role of Antimicrobial-Protected Device Polymers in the Fight Against Antibiotic-Resistant Bacteria.” The session (Wednesday, Sept. 16, from 2:10 p.m.-2:40 p.m. ET) will review recent test results, which compared antimicrobial-treated polymer materials used to make medical devices to untreated materials in reducing the growth of antibiotic-resistant organisms.
At the Association for Vascular Access (AVA) Annual Scientific Meeting, Sept. 26-29, in Dallas, Moloney will talk about the effectiveness of controlled-released, silver-based antimicrobials to prevent antibiotic-resistant colonization on the surfaces of catheters. In her session, “Evaluating the Role of Embedded Antimicrobials in the Fight Against Antibiotic-Resistant Infections” (Monday, Sept. 28, from 3:00 p.m.-3:30 p.m. CT), Moloney will discuss how these antimicrobials fared in eliminating the growth of some of the most dangerous organisms, including CRE, MRSA, VRE and A. baumannii.
CONTACT: If you are a member of the media or an industry analyst and would like to meet with Moloney at the events, contact Megan Coyle at 347.603.5096 or meg(at)klncommunications.com.
About Sciessent LLC
Sciessent is a leading provider of customized antimicrobial solutions that enhance the value of customers’ products. Agion® antimicrobial solutions from Sciessent have been incorporated into a wide range of healthcare, industrial and consumer applications, including medical devices such as central-venous catheters and IV access ports, drinking-water applications like water filters and ice-making equipment, and textiles and apparel. The company’s brands include Agion, Agion Active and Sciessent Lava and are based on naturally occurring elements. Sciessent customers include leading international brands including Vygon, Medegen, Scotsman, Everpure, Follett, Honeywell, UnderArmour, Adidas, Reebok and Skechers.
The Agion® Antimicrobial is presently registered by the United States Environmental Protection Agency as a preservative and bacteriostatic agent for use in treated articles under 40 CFR 152.25a. The information presented herein is not intended to support or endorse public health claims for treated articles. The Agion Antimicrobial is also used in medical devices under the Food and Drug Administration in the US; those medical device claims are based on safety and efficacy testing and are limited to those approved by FDA. In the EU, the Agion Antimicrobial is used in medical devices under the Medical Device Directive: those medical device claims are based on safety and efficacy testing and are limited to those approved by the designated Competent Authorities and/or Notified Bodies.
Megan Coyle, KLN Communications, http://www.sciessent.com, +1 347-603-5096, [email protected]
Share this article